Multiple Sclerosis
Multiple sclerosis (MS) offers important challenges to understanding its complex genetics and molecular and immunological mechanisms, which eventually lead to relapsing and progressive clinical forms and a constellation of clinical manifestations. Along with the progress in knowledge, disease-modify...
Furkejuvvon:
| Materiálatiipa: | Online |
|---|---|
| Giella: | eaŋgalasgiella |
| Almmustuhtton: |
MDPI - Multidisciplinary Digital Publishing Institute
2022
|
| Fáttát: | |
| Liŋkkat: | ONIX_20220224_9783036530970_138 |
| Fáddágilkorat: |
Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!
|
| _version_ | 1869517890093318144 |
|---|---|
| collection | Directory of Open Access Books |
| description | Multiple sclerosis (MS) offers important challenges to understanding its complex genetics and molecular and immunological mechanisms, which eventually lead to relapsing and progressive clinical forms and a constellation of clinical manifestations. Along with the progress in knowledge, disease-modifying treatments and new therapeutic molecules have made an impact on the prognosis of the disease. Essential in the diagnostic identification process of MS is the differentiation of this major demyelinating disease with other inflammatory CNS disorders, including Neuromyelitis Optica and MOG antibody disease. MS is more prevalent in women; therefore, pregnancy and post-partum hormonal and immunological changes typically affect the clinical behavior of the disease. This Special Issue of Biomedicines addresses recent advances in the mechanistic genetic and immunological processes of MS, opening more options to future studies and to the consideration of further therapeutic possibilities. The issue discusses the application of modern therapies, including monoclonal antibodies, some still in the process of complete development, and the current strategies managing progressive MS. The aim of this issue is to stimulate basic and clinical research and promote observations on the ever-expanding and complex field of MS. Advancement in the understanding of the mechanisms and the clinical characterizations of this disease should result in improved therapeutic outcomes that reduce neurological and cognitive disability commonly associated with progressive disease. |
| format | Online |
| id | doab-20.500.12854ir-78841 |
| institution | Directory of Open Access Books |
| language | eng |
| publishDate | 2022 |
| publishDateRange | 2022 |
| publishDateSort | 2022 |
| publisher | MDPI - Multidisciplinary Digital Publishing Institute |
| publisherStr | MDPI - Multidisciplinary Digital Publishing Institute |
| record_format | ojs |
| spelling | doab-20.500.12854ir-788412024-03-30T23:22:12Z Multiple Sclerosis Rivera, Víctor M. multiple sclerosis genetics disease modifying therapies generic medicines association study reactive oxygen species NADPH oxidase CYBB autoimmunity axon cortex demyelination mitochondria myelin neurodegeneration oligodendrocyte progressive multiple sclerosis daclizumab relapsing multiple sclerosis CD25 innate immune system interleukin-2 drug reaction with eosinophilia systemic symptoms DRESS monoclonal antibodies anti-CD20 Ocrevus Rituxan Tysabri clinical trial disease modifying therapy demyelinating diseases cognitive impairment cognitive dysfunction stem cells autologous hematopoietic mesenchymal neuronal induced pluripotent human embryonic pregnancy post-partum treatment neuromyelitis optica spectrum disorders anti-MOG syndrome aquaporin 4-IgG myelin oligodendrocyte glycoprotein remyelination outcome measures biomarkers thema EDItEUR::M Medicine and Nursing Multiple sclerosis (MS) offers important challenges to understanding its complex genetics and molecular and immunological mechanisms, which eventually lead to relapsing and progressive clinical forms and a constellation of clinical manifestations. Along with the progress in knowledge, disease-modifying treatments and new therapeutic molecules have made an impact on the prognosis of the disease. Essential in the diagnostic identification process of MS is the differentiation of this major demyelinating disease with other inflammatory CNS disorders, including Neuromyelitis Optica and MOG antibody disease. MS is more prevalent in women; therefore, pregnancy and post-partum hormonal and immunological changes typically affect the clinical behavior of the disease. This Special Issue of Biomedicines addresses recent advances in the mechanistic genetic and immunological processes of MS, opening more options to future studies and to the consideration of further therapeutic possibilities. The issue discusses the application of modern therapies, including monoclonal antibodies, some still in the process of complete development, and the current strategies managing progressive MS. The aim of this issue is to stimulate basic and clinical research and promote observations on the ever-expanding and complex field of MS. Advancement in the understanding of the mechanisms and the clinical characterizations of this disease should result in improved therapeutic outcomes that reduce neurological and cognitive disability commonly associated with progressive disease. 2022-02-24T10:38:22Z 2022-02-24T10:38:22Z 2022 book ONIX_20220224_9783036530970_138 9783036530970 9783036530963 https://directory.doabooks.org/handle/20.500.12854/78841 eng image/jpeg Attribution 4.0 International https://mdpi.com/books/pdfview/book/4935 https://mdpi.com/books/pdfview/book/4935 MDPI - Multidisciplinary Digital Publishing Institute 10.3390/books978-3-0365-3097-0 10.3390/books978-3-0365-3097-0 46cabcaa-dd94-4bfe-87b4-55023c1b36d0 9783036530970 9783036530963 192 Basel open access |
| spellingShingle | multiple sclerosis genetics disease modifying therapies generic medicines association study reactive oxygen species NADPH oxidase CYBB autoimmunity axon cortex demyelination mitochondria myelin neurodegeneration oligodendrocyte progressive multiple sclerosis daclizumab relapsing multiple sclerosis CD25 innate immune system interleukin-2 drug reaction with eosinophilia systemic symptoms DRESS monoclonal antibodies anti-CD20 Ocrevus Rituxan Tysabri clinical trial disease modifying therapy demyelinating diseases cognitive impairment cognitive dysfunction stem cells autologous hematopoietic mesenchymal neuronal induced pluripotent human embryonic pregnancy post-partum treatment neuromyelitis optica spectrum disorders anti-MOG syndrome aquaporin 4-IgG myelin oligodendrocyte glycoprotein remyelination outcome measures biomarkers thema EDItEUR::M Medicine and Nursing Multiple Sclerosis |
| title | Multiple Sclerosis |
| title_full | Multiple Sclerosis |
| title_fullStr | Multiple Sclerosis |
| title_full_unstemmed | Multiple Sclerosis |
| title_short | Multiple Sclerosis |
| title_sort | multiple sclerosis |
| topic | multiple sclerosis genetics disease modifying therapies generic medicines association study reactive oxygen species NADPH oxidase CYBB autoimmunity axon cortex demyelination mitochondria myelin neurodegeneration oligodendrocyte progressive multiple sclerosis daclizumab relapsing multiple sclerosis CD25 innate immune system interleukin-2 drug reaction with eosinophilia systemic symptoms DRESS monoclonal antibodies anti-CD20 Ocrevus Rituxan Tysabri clinical trial disease modifying therapy demyelinating diseases cognitive impairment cognitive dysfunction stem cells autologous hematopoietic mesenchymal neuronal induced pluripotent human embryonic pregnancy post-partum treatment neuromyelitis optica spectrum disorders anti-MOG syndrome aquaporin 4-IgG myelin oligodendrocyte glycoprotein remyelination outcome measures biomarkers thema EDItEUR::M Medicine and Nursing |
| topic_facet | multiple sclerosis genetics disease modifying therapies generic medicines association study reactive oxygen species NADPH oxidase CYBB autoimmunity axon cortex demyelination mitochondria myelin neurodegeneration oligodendrocyte progressive multiple sclerosis daclizumab relapsing multiple sclerosis CD25 innate immune system interleukin-2 drug reaction with eosinophilia systemic symptoms DRESS monoclonal antibodies anti-CD20 Ocrevus Rituxan Tysabri clinical trial disease modifying therapy demyelinating diseases cognitive impairment cognitive dysfunction stem cells autologous hematopoietic mesenchymal neuronal induced pluripotent human embryonic pregnancy post-partum treatment neuromyelitis optica spectrum disorders anti-MOG syndrome aquaporin 4-IgG myelin oligodendrocyte glycoprotein remyelination outcome measures biomarkers thema EDItEUR::M Medicine and Nursing |
| url | ONIX_20220224_9783036530970_138 |